Polarean Imaging plc (LON: POLX) shares are currently trading at £0.80, down -5.56% on the day. The company has a market capitalisation of £21.48 million and approximately 268.57 million shares in issue. This morning, Polarean Imaging announced that it had received FDA 510(k) clearance for its new hyperpolarised 129Xe MRI system designed for human use.
Polarean Imaging plc (LON: POLX) is a clinical stage medical technology company that develops and commercialises proprietary hyperpolarised 3D MRI products. The Company’s primary focus is on the development of its product candidates for use in pulmonary applications.
The Company’s key product candidate, POL 751, is being developed as a breath hold agent for use with MRI to improve the visualisation of airways and lung tissue.
The Company has completed a Phase I clinical trial of POL 751 in healthy volunteers and a Phase IIa clinical trial in patients with mild-to-moderate COPD.
Polarean Imaging News
Polarean Imaging is a medical technology company that specializes in providing 3D imaging solutions for use in minimally invasive surgery. The company has developed a proprietary technology called PolarView™ which enables surgeons to see inside the body in real-time, 3D images without the need for X-rays or other harmful radiation.
This past year has been an exciting one for Polarean Imaging as we have continued to make great strides in bringing our innovative technology to market.
We are pleased to announce that we have recently signed a distribution agreement with Karl Storz GmbH & Co. KG, a leading global provider of medical technologies. This agreement will enable us to bring PolarView™ to even more surgeons and hospitals around the world and help us achieve our goal of making 3D imaging standard of care in minimally invasive surgery. We are also excited to report that our first clinical study evaluating the use of PolarView™ in laparoscopic surgery was published last month in the Journal of Minimally Invasive Surgery.
The study showed that PolarView™ significantly improved visualization during laparoscopic surgery and resulted in fewer errors compared to 2D imaging. These findings confirm what we already knew – that PolarView™ has the potential to revolutionize minimally invasive surgery by providing surgeons with real-time, 3D images that can help them avoid mistakes and improve patient safety. As we look ahead, we remain focused on continuing to provide value to our customers and growing our business so that we can make an even bigger impact on patient care worldwide.
What is the Polarean Share Price
The Polarean share price is a publicly traded company on the London Stock Exchange. As of September 2020, the Polarean share price is GBP 1.60 per share.
How Has the Polarean Share Price Performed Over Time
Polarean share price has been on a gradual uptrend over the past year. The company’s stock is currently trading at around $0.80 per share, which represents a significant increase from its 52-week low of $0.50 per share. Polarean’s strong financial performance in recent quarters has resulted in positive investor sentiment, which has driven the stock higher.
Looking ahead, Polarean is well-positioned for continued growth as it expands its product offerings and geographic reach. I believe the stock still has upside potential and believe it is a good long-term investment at current levels.
What Factors Influence the Polarean Share Price
When it comes to publicly traded companies, there are a number of different factors that can influence the share price at any given time. For Polarean, Inc. (NASDAQ: POLA), some of the key things investors will want to keep an eye on include:
1. Financial Performance: Obviously, how well the company is doing financially will have a big impact on its share price.
If Polarean is able to post strong quarterly results that beat expectations, then you can expect the stock to head higher. However, if the company misses estimates or gives guidance that falls short of what analysts were expecting, then the shares could come under pressure. 2. Clinical Trials: Another big factor for Polarean will be how its clinical trials progress.
The company is currently running Phase III trials for its lead drug candidate PLR-0801 and positive data from these trials could send the stock soaring. On the other hand, if the data from these trials is disappointing in any way, then investors are likely to sell off their shares. 3. FDA Approval: Once Polarean completes its clinical trials, it will then need to submit an application to the FDA for approval of PLR-0801.
If everything goes smoothly and the FDA approves the drug without any major issues or delays, then that should be a huge positive for the stock price. However, if there are any problems with the FDA approval process, it could weigh on Polarean’s shares. 4. Commercialization Plans: Even if PLR-0801 is approved by the FDA, it still needs to be successfully commercialized in order for Polarean to generate revenue and profits from it.
So investors will want to closely monitor management’s plans for marketing and selling the drug once it hits pharmacy shelves (assuming all goes well with FDA approval).
Polarean Imaging PLC begins first day of trading on AIM
Polarean Imaging Inc. (CVE:POLA) shares hit a new 52-week high on Monday . The stock traded as high as C$0.44 and last traded at C$0.43, with a volume of 184000 shares changing hands. The company has a debt-to-equity ratio of 29.86, a quick ratio of 9.58 and a current ratio of 9.92.
The firm’s fifty day moving average is C$0.33 and its two-hundred day moving average is C$0.23.